Abstract 465TiP
Background
Management of musculo-skeletal cancers patients has changed significantly with change in treatment paradigm from amputation to limb conservation. Limb Salvage Surgery (LSS) is now the standard of care. Moreover, increase in survival rates following advancement in the available multimodality treatment has lead to increased interest regarding the quality of life (QOL) and functional outcomes of the survivor patients. Unfortunately, all the QoL studies in published literature pertain to western population. This study aims to determine the functional outcomes and quality of life after performing limb salvage surgery in extremity sarcoma patients in Indian population in tertiary care hospital.
Trial design
Observational study Inclusion criteria- extremity sarcoma patients treated with either limb salvage surgery or amputation between the year Jan 2017 to Dec 2022. Extremities sarcomas includes bone tumors and soft tissue sarcomas between 14 and 50 years of age. Exclusion criteria-Non extremities sarcoma patients and patients with rotationplasty / turn-o-plasty procedures done Patients’ baseline socio-demographic and clinical characteristics (age, gender, morphology and the type of surgical intervention) as well as orthopedic or oncological complications occurring during the follow-up will be derived from the medical record. Questionnaires concerning QoL and functional outcomes which will be sent by post / telephonically or an interview with the investigators on outpatient basis. Assessment tools: Functional outcome will be measured using the Toronto extremity salvage score, Musculoskeletal tumor society score while Quality of life will be assessed using the EORTC QLQ-C30 QoL scale. Statistical Analysis: Descriptive analysis of quantitative parameters will be expressed as means and standard deviation. Categorical data will be expressed as absolute number and percentage. Independent Student's t-test will be used for testing of mean difference between independent groups. Cross tables will be generated and Chi square test will be used for testing of associations. P-value < 0.05 will be considered statistically significant. All analysis will be done using SPSS software, version 24.0.
Clinical trial identification
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
429P - Cancer and COVID-19 in India: Assessing the impact in a nationwide survey
Presenter: Bharti Devnani
Session: Poster viewing 06
430P - Single-cell spatial architecture of tumour microenvironment in patients with in-transit melanoma (ITM)
Presenter: Camelia Quek
Session: Poster viewing 06
431P - Alveolar soft part sarcomas: A tertiary care Indian centre experience
Presenter: Jyoti Bajpai
Session: Poster viewing 06
432P - Representation of countries and gender in abstracts at the 2022 American Society of Clinical Oncology Annual Scientific Meeting (ASCO ASM)
Presenter: Laure-Anne Teuwen
Session: Poster viewing 06
433P - Variations in radiation oncology treatment access in Asia and its implications on cancer care
Presenter: Abhishek Krishna
Session: Poster viewing 06
434P - Outcome of high grade glioma patients: A single institution experience
Presenter: Adeeba Zaki
Session: Poster viewing 06
435P - The pattern of presentation of cancer in young adults from a tertiary care centre: A cause for concern
Presenter: Deepa Joseph
Session: Poster viewing 06
436P - Oncologic outcomes in patients with extraskeletal Ewing’s sarcoma (EES): A tertiary care centre experience
Presenter: Ashish Gulia
Session: Poster viewing 06
437P - The prevalence of burnout among medical oncology fellows-in-training in the Philippines: A cross-sectional study
Presenter: Daphne Lee
Session: Poster viewing 06
438P - Estimating scenarios for survival time in patients with metastatic melanoma receiving immunotherapy or targeted therapy
Presenter: Megan Smith-Uffen
Session: Poster viewing 06